Molecular epidemiology of genital human papillomavirus and Chlamydia trachomatis among patients attending a genitourinary medicine clinic - Will vaccines protect?

International Journal of STD and AIDS

Volumn 18, Issue 9, 2007, Pages 617-621

  Jalal, H ^a   Stephen, H ^a   Bibby, D F ^b   Sonnex, C ^a   Carne, Christopher A ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chlamydia trachomatis; Genitourinary diseases; Human papillomavirus; Molecular epidemiology; Sexually transmitted diseases

Indexed keywords

OUTER MEMBRANE PROTEIN; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHLAMYDIA TRACHOMATIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MOLECULAR EPIDEMIOLOGY; NUCLEOTIDE SEQUENCE; OUTPATIENT DEPARTMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; AGED; ALPHAPAPILLOMAVIRUS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; GENOTYPE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHYLOGENY; PREVALENCE;

EID: 44349149794     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646207781568501     Document Type: Article

References (30)

1. Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. vol 64. Lyon, France: International Agency for Research on Cancer, 1995
2. Lowy DR, Schiller JT. Papillomaviruses and cervical cancer; pathogenesis and vaccine development. J Natl Cancer Inst Monogr 1998;23:27-30
3. Koutsky LA, Kiviat NB. Human papillomavirus infections. In: Holmes KK, Mardh PA, Sparling PF et al., eds. Sexually Transmitted Diseases. 3rd edn. New York, NY: McGraw-Hill, 1999;347-60
4. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27
5. Ho GYF, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8
6. Antilla T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001;285:47-51
7. Jalal H, Stephen H, Al-Suwaine A, et al. The superiority of polymerase chain reaction over an amplified enzyme immunoassay for the detection of genital chlamydial infections. Sex Transm Infect 2006;82:37-40
8. Strauss S, Sastry P, Sonnex C, Edwards S, Gray J. Contamination of environmental surfaces by genital human papillomaviruses. Sex Transm Infect 2002;78:135-8
9. McCartney RA, Walker J, Scoular A. Detection of Chlamydia trachomatis in genitourinary medicine attendees: comparison of strand displacement amplification and the ligase chain reaction. Br J Biomed Sci 2001;58:235-238
10. Sayada C, Denamur E, Xerri B, Orfila J, Catalan F, Elion J. Epidemiology of Chlamydia trachomatis using analysis of gene encoding of the major outer membrane protein. Pathol Biol (Paris) 1992;40:583-9
11. Oehme A, Gaschler G, Straube E. Genotyping of Chlamydia trachomatis strains from cultured isolates and nucleic acid amplification test-positive specimens. Int J Med Microbiol 2003;293:225-8
12. Morre SA, Rozendall L, van Valkengoed IG, et al. Urogenital Chlamydia trachomatis serovars in men and women with symptomatic or asymptomatic infection: an association with clinical manifestations? J Clin Microbiol 2000;38:2292-6
13. Lysen M, Osterlund A, Rubin CJ, Persson T, Herrmann B. Characterization of ompA genotypes by sequence analysis of DNA from all detected cases of Chlamydia trachomatis infections during 1 year of contact tracing in a Swedish county. J Clin Microbiol 2004;42:1641-1647
14. Suchland RJ, Eckert LO, Hawes SE, Stamm WE. Longitudinal assessment of infecting serovars of Chlamydia trachomatis in Seattle Public Health clinics: 1988-1996. Sex Transm Dis 2003;30:357-61
15. van Duynhoven YTHP, Ossewaarde JM, Derksen-Nawrocki RP, van der Meijden WI, van der Laar MJW. Chlamydia trachomatis genotypes: correlation with clinical manifestations of infection and patients' characteristics. Clin Infect Dis 1998;26:314-22
16. Geisler WM, Suchland RJ, Whittington WL, Stamm WE. The relationship of serovar to clinical manifestations of urogenital Chlamydia tachomatis infection. Sex Transm Dis 2003;30:160-5
17. Dean D, Oudens E, Bolan G, et al Major outer membrane protein variants of Chlamydia trachomatis are associated with severe upper genital tract infection and histopathology in San Francisco. J Infect Dis 1995;172:1013-22
18. Workowski KA, Stevens CE, Suchland RJ, et al. Clinical manifestations of genital infection due to Chlamydia trachomatis in women; differences related to serovar. Clin Infect Dis 1994;19:756-60
19. van der Laar MJ, van Duynhoven YT, Fennema JS, et al. Differences in clinical manifestations of genital chlamydial infections related to serovars. Genitourin Med 1996;72:261-5
20. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004;57:68-71
21. Silins I, Ryd W, Strand A, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005;116:110-15
22. Samoff E, Koumans EH, Markowitz LE, et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005;162:668-75
23. Fischer N. Chlamydia trachomatis infection in cervical intraepithelial neoplasia and invasive carcinoma. Eur J Gynaecol Oncol 2002;23:247-50
24. Smith JS, Munoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the aetiology of invasive cancer in Brazil and the Philippines. J Infect Dis 2002;185:324-31
25. Wallin K-L, Wiklund F, Luostatarinen T, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer 2002;101:371-4
26. Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines. Ann Pharmacother 2006;40:1344-52
27. Fox M. Immunization Advisory Panel recommends HPV vaccine for all girls. www.medscape.com/viewarticle/537674
28. Smith JF, Brownlow MK, Brown MJ, et al. Antibodies cross-neutralise pseudovirion infection of vaccine-related HPV types. PL 1-6. 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic, September 2006
29. Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus (HPV) vaccine on the burden of cervical disease in the UK P-200. 23rd International Papillomavirus Conference and Clinical Workshop. Prague, Czech Republic. September 2006
30. Rupp RE, Stanberry LR, Rosenthal SL. Vaccines for sexually transmitted infections. Pediatr Ann 2005;34:818-24